Financing ·
PAVmed Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 9, 2026, establishing an…
PAVMPAVmed Inc.
PAVmed Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 9, 2026, establishing an at-the-market equity offering program. The company may sell up to $9,400,000 of common stock through the agent, paying a 3.0% commission plus legal reimbursement fees capped at $65,000 for execution and quarterly amounts thereafter. Net proceeds are intended for working capital and general corporate purposes. PAVmed Inc. operates in the medical device industry, developing minimally invasive treatments for venous disease.